SCHEMBL1010470

SCHEMBL1010470

O=C(Nc1ccc2[nH]nnc2c1)Oc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.54
ALDH1A1 P00352 8/20 0.51
MAPT P10636 5/20 0.51
KDM4E B2RXH2 3/20 0.51
RAD51 Q06609 2/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
THRB P10828 1/20 0.47
GFER P55789 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GAA P10253 3/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
HSD17B10 Q99714 1/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
USP2 O75604 1/20 0.42
PORCN Q9H237 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13411810 0.90 ALDH1A1 (0.51) BRD4ALDH1A1MAPTKDM4ERAD51
SCHEMBL7773324 0.80 NPC1 (0.59) BRD4ALDH1A1MAPTKMT2AMEN1
SCHEMBL8021163 0.77 ELANE (0.51) ALDH1A1MAPTKDM4ECYP1A2POLB
SCHEMBL9147984 0.77 BRD4 (0.55) BRD4ALDH1A1MAPTKDM4ERAD51
SCHEMBL1080719 0.77 MAPT (0.57) ALDH1A1MAPTKMT2AMEN1TDP1
SCHEMBL15146078 0.76 ROCK2 (0.67) BRD4ALDH1A1MAPT
SCHEMBL1247686 0.76 ROCK2 (0.55) ALDH1A1MAPTKDM4EPOLBKMT2A
SCHEMBL1156215 0.76 PEPD (0.42) ALDH1A1MAPTKMT2AMEN1GFER
SCHEMBL9172845 0.75 ROCK2 (0.54) ALDH1A1MAPTKDM4EPOLBKMT2A
SCHEMBL14360693 0.75 CA2 (0.46) ALDH1A1MAPTKDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
US-5888694-A MATERIAL CONTAINING COMPOUND HAVING ADSORPTION ACCELERATING GROUP AND QUATERNIZED NITROGEN-CONTAINING HETEROCYCLIC RING;FORMING HIGH CONTRAST IMAGES FUJI PHOTO FILM CO., LTD. (JP) 1999-03-30 US disclosed
EP-0267598-B1 Superhigh contrast negative-type silver halide photographic material FUJI PHOTO FILM CO LTD (JP) 1995-02-08 EP disclosed
US-5192647-A Forming latent images FUJI PHOTO FILM CO., LTD. (JP) 1993-03-09 US disclosed
US-4851321-A HYDRAZINE DERIVATIVE, HETEROCYCLIC CONTRAST ENHANCER FUJI PHOTO FILM CO., LTD. (JP) 1989-07-25 US disclosed
EP-0267598-A2 Superhigh contrast negative-type silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1988-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC BRD4 273/4885ALDH1A1 360/4885MAPT 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.